Browse > Article

Pharmacokinetic Interaction between Nifedipine and Paclitaxel in Rats  

최준식 (조선대학교 약학대학)
이종기 (초당대학교 의약관리학부)
Publication Information
YAKHAK HOEJI / v.48, no.1, 2004 , pp. 1-5 More about this Journal
Abstract
The purpose of this study was to investigate the effect of coadministration and 3 days-pretreatmemt of niledipine (2, 10 mg/kg) on the pharmacokinetic parameters and bioavailability of paclitaxel (50 mg/kg) after oral administration in rats. Coadministration of nifedipine with paclitaxel did alter the $C_{max}$ (115${\pm}$29 ng/ml without nifedipine; 135${\pm}$35 ng/ml with nifedipine (10 mg/kg): p<0.05) and AUC (188${\pm}$459 ng/mlㆍhr with-out nifedipine; 2546${\pm}$642 ng/mlㆍhr with nifedipine; p<0.05). Three days treatment of nifedipine on the prior to paclitaxel administration increased the $t_{1/2}$ 〔9.90${\pm}$2.47 hr without nifedipine; 12.37${\pm}$3.12 hr with nifedipine (2 mg/kg): 12.83${\pm}$3.32 hr with nifedipine (10 mg/ml); p<0.05] and AUC [1833${\pm}$459 ng/mlㆍhr without nifedipine; 2663${\pm}$648 ng/mlㆍhr with nifedipine (2 mg/kg): 3006${\pm}$734 ng/mlㆍhr with nifedipine (10 mg/ml): p <0.05]. Drug interaction between nifedipine and paclitaxel decreased the elimination rate constant and increased the oral bioavailability of paclitaxel. On the basis of the results of this study, it might be considered that nifedip ine may inhibit cytochrome P450, which are engaged in paclitaxel metabolism, result in increased $t_{1/2}$ and AUC of paclitaxel. However, further study should be conducted to clarify the roles of cytochrome P450 and P-glycoprotein on paclitaxel bio-availability wit/or without nifedipine.
Keywords
paclitaxel; pharmacokinetics; nifedipine; drug interaction; coadministration; pretreatment;
Citations & Related Records
연도 인용수 순위
  • Reference
1 Phase Ⅱ trial of taxol in patients with metastatic renal cell carcinoma /
[ Einzig,A.I.;Gorowski,E.;Sadloff,J.(et al.) ] / Cancer Invest   DOI   ScienceOn
2 Short communication; Taxol metabolism in rat hepatocytes /
[ Walle,T. ] / Biochem. Pharmacol.   DOI   ScienceOn
3 Nifedipine. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic efficacy, in ischaemic heart disease, hypertension and relatd cardiovascular disorders /
[ Sorkin,E.M.;Clissold,S.P.;Brogden,R.N. ] / Drugs   DOI   ScienceOn
4 Restoration of doxorubicin responsiveness in doxorubicin-resistant P388 murine leukaemia cells /
[ Ramu,A.;Spanier,R.;Rahamimoff,H.;Fuks,Z. ] / Br. J. Cancer   DOI   ScienceOn
5 Oxidation of dihydro-pyridine calcium channel blockers and analogues by human liver cytochrome P-450 ⅢA4 /
[ Guengerich,F.P.;Brian,W.R.;Iwasaki,M.;Sari,M.A.;Baarnhielm,C.;Berntsson,P. ] / J. Med. Chem.
6 Sequences of taxol and cisplatin: A Phase I and pharmacologic study /
[ Rowinsky,E.K.;Gilbert,M.R.;McGuire,W.P.(et al.) ] / J. Clin. Oncol.   DOI
7 Phase I trial of taxol in patients with advanced malignancies /
[ Donehower,R.C.;Rowinsky,E.K.;Grochow,L.B.(et al.) ] / Cancer Treat. Rep.
8 Phase I trial of taxol given as a 24-hour infusion every 21 days: Responses seen in metastatic melanoma /
[ Wiernik,P.H.;Schwartz,E.L.;Einzig,A.(et al.) ] / J. Clin. Oncol.   DOI
9 Role of P-glycoprotein and cytochrome P450 3A in limiting oral absorption of peptides and peptidomimetics /
[ Wacher,V.H.;Silverman,J.A.;Zhang,Y.;Benet,L.Z. ] / J. Pharm. Sci.   DOI
10 LAGRAN program for area and monents in pharmacokinetic analysis /
[ Rocci,M.L.;Jusko,W.J. ] / Computer Program in Biomedicine   DOI   ScienceOn
11 Phase Ⅱ study and long-term follow up of patients treated with taxol for advanced ovarian adenocarcinoma /
[ Einzig,A.I.;Wiernik,P.H.;Sasloff,J.(et al.) ] / J. Clin. Oncol.   DOI
12 Phase I study of taxol and granulocyte stimulation factor in patients with refractory ovarian cancer /
[ Sarosy,G.;Kohn,E.;Stone,D.A.(et al.) ] / J. Clin. Oncol.   DOI
13 Transport and epithelial secretion of the cardiac glycoside, digoxin, by human intestinal epithelial(Caco-2) cells /
[ Cavet,M.E.;West,M.;Simmons,N.L. ] / Br. J. Pharmacol.   DOI   ScienceOn
14 Clinical Pharma-cokinetics of paclitaxel /
[ Sonnichsen,D.S.;Relling,M.V. ] / Clin. Pharmacokinet   DOI   ScienceOn
15 Effects of intestinal CYP3A4 and P-glycoprotein on oral drug absorption-theoretical approach /
[ Ito,K.;Kusuhara,H.;Sugiyama,Y. ] / Pharm. Res.   DOI   ScienceOn
16 A phase Ⅱ study of taxol in patients with malignant melanoma /
[ Einzig,A.I.;Hochster,H.;Wiernik,P.H.(et al.) ] / Invest. New. Drugs.
17 Phase Ⅱ trial of dexverapamil and epirubicin in patients with non-responsive metastatic breast cancer /
[ Lehnert,M.;Mross,K.;Schueller,J.;Thuerlimann,B.;Kroeger,N.;Kupper,H. ] / Br. J. Cancer   DOI   ScienceOn
18 Comparative pharmacology of calcium antagonists: nifedipine, verapamil and diltiazem /
[ Henry,P.D. ] / Am. J. Cardiol.   DOI   ScienceOn
19 Selective biotransformation of taxol to 6α-hydroxytaxol by human cytochrome P450 2C8 /
[ Rahman,A.;Korzekwa,K.R.;Grogan,J.;gonzalez,F.J.;Harris,J.W. ] / Cancer Res.
20 Effects of verapamail on the acute toxicity of doxorubicin in vivo /
[ Sridhar,R.;Dwivedi,C.;Anderson,J.;Baker,P.B.;Sharma,H.M.;Desai,P.;Engineer,F.N. ] / Journal of the National Cancer Institute   DOI
21 Taxol: A unique antineoplastic agent with significant activity in advanced ovarian epithelial neoplasm. /
[ McGuire,W.P.;Rowinsky,E.K.;Rosenheim,N.B.(et al.) ] / Ann. Intern. Med.   DOI   ScienceOn
22 Phase I study of taxol administered as a short iv infusion daily for 5 days /
[ Grem,J.L.;Tutsch,K.D.;Simon,K.L.(et al.) ] / Cancer Treat. Rep.
23 Modulation by verapamil of vincristine pharmacokinetics and toxicity in mice bearing human tumor xenografts /
[ Horton,J.K.;Thimmaiah,K.N.;Houghton,J.A.;Horowitz,M.E.;Houghton,P.J. ] / Biochemical Pharmacology   DOI   ScienceOn
24 Assay of paclitaxel (Taxol) in plasma and urine by high performance liquid chromatogrphy /
[ Manrin,N.;Catalin,J.;Blachon,M.F.;Durand,A. ] / J. Chromato. B.   DOI
25 Metabolism of taxol by human hepatic microsomes and liver slices: participation of cytochrome P450 3A4 and an unknown P450 enzyme. /
[ Harris,J.W.;Rahman,A.;Kim,B.R.;Guengerich,F.P.;Collins,J.M. ] / Cancer Res.
26 Determination of new anticancer drug, paclitaxel, in biological fluids by high performance liquid chromatography /
[ Mase,H.;Hiraoka,M.;Suzuki,F. ] / Yakugaku. Zasshi   DOI
27 Circumvention of vincristine and Adriamycin resistance in vitro and in vivo by calcium influx blockers /
[ Tsuruo,T.;Iida,M.;Nojiri,H.;Tsukagoshi,S.;Sakurai,Y. ] / Cancer Res.
28 The barrier function of CYP3A4 and Pglycoprotein in the small bowel. /
[ Watkins,P.B. ] / Adv. Drug Deliv. Rev.   DOI
29 Variability in human cytochrome P450 paclitaxel metabolism /
[ Sonnichsen,D.S.;Liu,Q.;Schuetz,E.G.;Schuetz,J.D.;Pappo,A.;Relling,M.V. ] / J. Pharmacol. Exp. Ther.
30 Phase I study of taxol using a 50day intermittent schedule /
[ Legha,S.S.;Tenney,D.M.;Krakhoff,I.R. ] / J. Clin. Oncol.   DOI